Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Cellect Biotechnology Ltd. (NASDAQ: APOP).

Full DD Report for APOP

You must become a subscriber to view this report.


Recent News from (NASDAQ: APOP)

Cellect Biotechnology Ltd Provides Corporate Update and Reports First Quarter 2018 Financial Results
TEL AVIV, Israel , May 17, 2018 /PRNewswire/ -- Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology which enables the functional selection of stem cells, today provided a corporate update and announced financial results for the first quarter ended March 31, 20...
Source: PR Newswire
Date: May, 17 2018 16:59
Former GE Healthcare Executive to Join Cellect as Chief Business Officer
TEL AVIV, Israel , May 10, 2018 /PRNewswire/ -- Cellect Biotechnology Ltd. (Nasdaq: APOP), a developer of a novel stem cell manufacturing technology, announced that it will open a U.S. center of operations to be led by Andrew Sabatier . Mr. Sabatier has over 20 years of experience...
Source: PR Newswire
Date: May, 10 2018 07:00
Cellect Bio up 21% premarket on advancement of new stem cell production technique
Thinly traded nano cap Cellect Biotechnology (NASDAQ: APOP ) is up  21%  premarket on modestly higher volume on the heels of its announcement that it has successfully completed proof-of-concept testing of ApoTainer, a new scalable method for manufacturing stem cells that it says ...
Source: SeekingAlpha
Date: April, 09 2018 07:59
Cellect Announces a Major Milestone for Enabling Stem Cells Production
TEL AVIV, Israel , April 9, 2018 /PRNewswire/ -- Cellect Biotechnology Ltd. (Nasdaq: APOP), a developer of a novel stem cell enabling technology, announced that it has successfully completed the proof of concept testing of its first in type new product prototype, ApoTainer™ using C...
Source: PR Newswire
Date: April, 09 2018 07:00
Cellect Biotechnology reports Q4 results
Cellect Biotechnology (NASDAQ: APOP ): Q4 EPADS of -NIS0.56 Press Release More news on: Cellect Biotechnology Ltd., Earnings news and commentary, Healthcare stocks news, ,
Source: SeekingAlpha
Date: March, 19 2018 16:25
Cellect Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2017 Financial Results
TEL AVIV, Israel , March 19, 2018 /PRNewswire/ -- Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology which enables the functional selection of stem cells, today provided a corporate update and announced financial results for the fourth quarter and full year en...
Source: PR Newswire
Date: March, 19 2018 16:15
Frost & Sullivan Publishes an Update Report on Cellect Biotechnology Ltd.: Capital raising of $4M will support the company's clinical and strategic goals; price target unchanged
Frost & Sullivan Publishes an Update Report on Cellect Biotechnology Ltd.: Capital raising of $4M will support the company's clinical and strategic goals; price target unchanged Frost & Sullivan Publishes an Update Report on Cellect Biotechnology Ltd.: Capital raising of $4...
Source: Canada Newswire
Date: February, 01 2018 11:43
Cellect Biotechnology Announces $4 Million Registered Direct Offering
TEL AVIV, Israel , January 29, 2018 /PRNewswire/ -- Cellect Biotechnology Ltd. (Nasdaq: APOP), a developer of stem cells selection technology, announced that it has entered into securities purchase agreements with certain institutional investors for gross proceeds of approximately $4...
Source: PR Newswire
Date: January, 29 2018 08:00
Cellect Announces Opening of a Second Clinical Trial Site and Approval from Safety Board (DSMB) for Dose Escalation
TEL AVIV, Israel , Jan. 16, 2018 /PRNewswire/ -- Cellect Biotechnology Ltd. (Nasdaq: APOP), a developer of a novel stem cell selection technology, announced that it has signed an agreement with the Hadassah Medical Center to conduct clinical trials on cancer patients in Cellect's ongoing ...
Source: PR Newswire
Date: January, 16 2018 07:00
Your Daily Pharma Scoop: Ablynx Takeover Bid, Celgene Acquires Impact Biomedicines, Axovant Flops Again
Analysis of top Seeking Alpha coverage: Ablynx Today we will discuss the hostile takeover bid from Novo Nordisk ( NVO ) for clinical-stage Belgian biotech company Ablynx ( OTCPK:ABLYF ). On Monday , Novo made a euro 2.6 billion ($3.1 billion) offer to acquire Ablynx. Novo has offered ...
Source: SeekingAlpha
Date: January, 09 2018 11:02

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-214.754.924.97624.755,665
2018-08-205.004.76335.004.6521,442
2018-08-175.075.00125.1894.516276,763
2018-08-164.404.974.974.4023,817
2018-08-154.56454.47234.78974.4030,244

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-215003,10016.1290Cover
2018-08-202016,5263.0800Cover
2018-08-176,31838,43616.4377Cover
2018-08-163,65513,16827.7567Cover
2018-08-153,2816,81848.1226Short

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on APOP.


About Cellect Biotechnology Ltd. (NASDAQ: APOP)

Logo for Cellect Biotechnology Ltd. (NASDAQ: APOP)

Not available

 

Contact Information

 

 

Current Share Structure

     


    Recent Filings from (NASDAQ: APOP)

    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: May, 17 2018
    Securities offered to employees under employee benefit plans
    Filing Type: S-8Filing Source: edgar
    Filing Date: May, 17 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: May, 10 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: April, 09 2018
    Notice from the SEC of registration effectiveness
    Filing Type: EFFECTFiling Source: edgar
    Filing Date: April, 06 2018
    Post-effective amendment to an S-Type filing
    Filing Type: POS AMFiling Source: edgar
    Filing Date: March, 21 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: March, 19 2018
    Annual and transition report of foreign private issuers under sections 13 or 15(d)
    Filing Type: 20-FFiling Source: edgar
    Filing Date: March, 19 2018
    Amendment to the SC 13G filing
    Filing Type: SC 13G/AFiling Source: edgar
    Filing Date: February, 20 2018
    Prospectus filed under Rule 424(b)(3)
    Filing Type: 424B3Filing Source: edgar
    Filing Date: February, 09 2018

     

     


    Daily Technical Chart for (NASDAQ: APOP)

    Daily Technical Chart for (NASDAQ: APOP)


    Stay tuned for daily updates and more on (NASDAQ: APOP)

    It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

    More to come on (NASDAQ: APOP)

    Do your DD and if you choose, be ready to go!


     

    The Research: All source information contained in this email is from the public sources mentioned below.

     

     
     

    Thank you

    DD Report
    @DDReports

     

     


    Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in APOP is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of APOP and does not buy, sell, or trade any shares of APOP. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/